21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)

21 CFR Part 211 establishes the minimum CGMP requirements for the preparation of finished pharmaceutical products for human use. The regulation ensures that every batch of drug product meets standards for identity, strength, quality, and purity. The “Current” in CGMP reflects the requirement to use up-to-date methods, facilities, and controls that are considered state-of-the-art in assuring drug quality.

Scope

• Applies to manufacturing, processing, packing, or holding of drug products intended for administration to humans.

• Covers both U.S.-based and foreign manufacturers whose products are imported into the United States.

• Encompasses operations from receipt of raw materials through final product distribution.

• Addresses all dosage forms of finished pharmaceuticals. It does not apply to the manufacturing of bulk drug substances (also known as Active Pharmaceutical Ingredients or APIs), which are covered under FDA's adopted guidance, ICH Q7, Good Manufacturing Practice for Active Pharmaceutical Ingredients.

The core principle of Part 211 is that quality must be built into the product at every stage, not just tested for at the end. By ensuring that every batch consistently meets its established standards for identity, strength, quality, and purity, CGMP preserves the safety and efficacy that were demonstrated during clinical development.

• Robust process design and control.

• Rigorous, contemporaneous documentation.

• An empowered Quality Control Unit (QCU) with authority over product quality decisions.

• Subpart B (Personnel): An independent Quality Control Unit (QCU) must approve or reject all materials, products, and procedures. Personnel must be qualified and receive ongoing training in CGMP and hygiene.
• Subparts C & D (Facilities & Equipment): Facilities and equipment must be designed, maintained, and cleaned to prevent contamination and mix-ups. All maintenance, cleaning, and calibration activities must have written procedures and be recorded in logs.
• Subpart I (Lab Controls): Written, scientific specifications and testing procedures are required. A stability program must be in place to determine expiration dates. Sterility testing must be performed where applicable, and reserve samples from each batch must be retained.
• Subpart J (Records): Master Production and Control Records must provide the template for production. Batch Production and Control Records must document the complete history of each batch. Batch records (BPCRs) must document the complete history of each batch. Distribution records must ensure traceability for recalls, and all complaints must be investigated and documented.